Newsroom
Category
September 8, 2020
SAN ANTONIO (Sept. 8, 2020) – Registration is now open for the fifth annual San Antonio Combat PTSD Conference, slated for Oct. 22-23, 2020. The conference will feature leaders in the field reporting advances in the assessment and treatment of combat-related post-traumatic stress disorder and co-occurring conditions. Pre-conference continuing education and clinical training opportunities are […]
September 8, 2020
Although it’s not a cure for ALS, an oral drug slowed patients’ rate of functional decline in a clinical trial that included five patients at UT Health San Antonio. If the finding is repeated in larger trials, the drug could give families more time with their loved ones who have ALS. The New England Journal […]
September 4, 2020
Multisystem inflammatory syndrome in children (MIS-C), believed to be linked to COVID-19, damages the heart to such an extent that some children will need lifelong monitoring and interventions, said the senior author of a medical literature review published Sept. 4 in EClinicalMedicine, a journal of The Lancet. Case studies also show MIS-C can strike seemingly […]
September 2, 2020
Contact: Cliff Despres, Communications, Salud America!, UT Health San Antonio 210-562-6517, despres@uthscsa.edu The #JuntosStopCovid campaign has culturally relevant fact sheets, role model videos, and infographics to help Latino families take action to slow the spread of COVID-19 SAN ANTONIO — COVID-19 continues to disproportionately impact Latinos, killing more than 33,000 and hospitalizing many more of […]
August 26, 2020
Labor Day is nearly here, and again, South Texas, we must not let our guard down. Experts from UT Health San Antonio urge everyone to wear masks, observe 6-foot social distance, wash hands vigorously, and avoid indoor and large gatherings. Stay in your family bubble as much as possible and wear a mask if you […]
August 25, 2020
In the war on cancer and other diseases including COVID-19, old drugs approved for other conditions are being studied for new purposes. It’s a strategy that will now be tested in Alzheimer’s disease with a drug called rapamycin. A $2 million grant will enable a double-blind, placebo-controlled clinical trial in which 40 individuals with mild […]
